Clarification12 Nov 2026, 06:52 pm
Suraksha Diagnostic Issues Corrigendum for Q2 & H1 FY27 Financials
AI Summary
Suraksha Diagnostic Limited has issued a corrigendum to its press release dated November 10, 2026, regarding its financial performance for the quarter and half-year ended September 30, 2026. The company identified inadvertent errors in the initial intimation and has provided corrected details for key operational highlights, including total tests, average revenue per test, and other financial metrics. The updated press release confirms strong performance with Profit After Tax (PAT) growing by 69% year-on-year in Q2 FY27 and EBITDA growing by 45% year-on-year in Q2 FY27. The company also highlighted network expansion with five new centers opened during the quarter.
Key Highlights
- Suraksha Diagnostic corrects previously intimated Q2 & H1 FY27 financial performance data.
- PAT grew 69% YoY in Q2 FY27, EBITDA grew 45% YoY in Q2 FY27.
- Company opened five new centers, expanding its network.
- Genomics business is expected to become a meaningful contributor.
- Focus remains on sustainable growth and disciplined expansion.
Price Impact
More from SURAKSHA